MESA LABORATORIES INC /CO/ — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Mesa Laboratories reported Q1 FY27 (ended June 30, 2026) revenues of $60.1M, up 1.0% YoY; core organic growth was 0.4%. Non-GAAP adjusted operating income (AOI) excluding unusual items was $15.4M (25.6% margin), up 19.5% YoY. The company repaid $8.7M in debt and reduced net leverage ratio to 1.85x (target: 2.0x). Segment performance: SDC (41% of revenue) declined 3.6% due to fulfillment challenges; BPD grew 5.0%; CS grew 7.6%; CG was essentially flat. New CEO Siddhartha Kadia (100 days in) stated focus on disciplined execution; full-year guidance promised in November.
Why this rating
Modest 1% topline growth with execution headwinds (SDC) offset by margin expansion and debt reduction. Relative to $358M market cap, $60M quarterly revenue and $15.4M AOI are baseline operations. New leadership and operational improvements noted but not yet proven; no material M&A, strategic shifts, or earnings surprises.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.